azithromycin and desloratadine: label evidence and limits

The desloratadine label reports increased desloratadine and metabolite concentrations with azithromycin in controlled studies, but no clinically relevant changes in the safety profile.

Which products this evidence covers

Oral desloratadine tablets; controlled-study exposure finding.

What this finding does and does not establish

The absence of a clinically relevant safety change in those studies is an essential qualification. An exposure change alone does not validate CDI’s moderate severity category or prove universal safety.

Supporting label passage

In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See CLINICAL PHARMACOLOGY ( 12.3 )].

Read the product label on DailyMed. Section: 7.1 Inhibitors of Cytochrome P450 3A4. Compared label version 17, dated 2026-06-30.

How this brief was prepared

This brief uses an AI-assisted source comparison dated 2026-10-16. The label version and supporting passage were checked again on 2026-10-28. Independent clinical review has not been recorded. The comparison does not validate CDI's severity category or determine individual treatment.

Discuss your exact medicines with your pharmacist

Ask whether the cited formulation and route apply to your products and circumstances. Confirm medication decisions with your pharmacist or prescriber before changing treatment.

Check your medication list with CDI.